Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sarepta Therapeutics

Summit takes clinical trial participant search online

Hopes to broaden reach of its Duchenne muscular dystrophy study

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

Santhera facing long delay for muscular dystrophy drug in US

FDA rejects accelerated marketing application for Raxone to await phase II trial results

Biomarin

BioMarin gives up on muscular dystrophy drug

Makes ‘difficult but necessary’ decision to abandon exon-skipping therapy Kyndrisa

- PMLiVE

FDA rejects PTC’s application for muscular dystrophy drug

Says Translarna filing not “sufficiently complete” to permit full review

Harnessing complexity

Companion diagnostics in oncology

- PMLiVE

Mixed news for gene therapies at ASH conference

GSK unveils successful trial, but there was disappointing news for Bluebird

- PMLiVE

Prosensa says it could file muscular dystrophy drug this year

Drisapersen still shows promise despite GSK’s decision to terminate collaboration

- PMLiVE

Santhera closer to filing for muscular dystrophy drug

Catena/Raxone slows loss of lung function in late stage trial

- PMLiVE

GSK ends muscular dystrophy deal

Terminates rare disease collaboration with Prosensa after trial disappointment

- PMLiVE

Boehringer backs gene therapy firm Eyevensys

Invests in French eye disease specialist

- PMLiVE

First efficacy data for GSK/Prosensa’s muscular dystrophy candidate positive

Ups ante in race against Sarepta Therapeutics to market first Duchenne muscular dystrophy drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links